Harborside Completes Acquisition of its Desert Hot Springs Retail Location
OAKLAND, Calif.- Harborside Inc. (CSE: HBOR), (OTCQX: HBORF) announced, it has purchased 100% of the issued and outstanding equity interest of Accucanna LLC, the license holder of the Company’s Desert Hot Springs retail dispensary location, together with the real property relating to the DHS for a total consideration of US$4,918,263. Prior to closing of the Acquisition, Harborside had been operating the dispensary since December 2019 under a management services agreement.
“We are thrilled to add our Desert Hot Springs retail dispensary into our California retail store portfolio,” said Matt Hawkins, Interim CEO of Harborside. “As one of only two drive-through retail locations permitted in the state, and with our strategic location in the Coachella valley near the freeway, we are well-positioned to continue to service the local community and support the robust year-round tourism industry.”
In December 2019, Harborside announced that it opened DHS, the Company’s first retail location outside of the Bay Area. Located at 66205 Paul Road, Desert Hot Springs, CA, the 4,800 square foot facility is strategically located on Interstate 10 between Los Angeles and Coachella and serves both medical and adult-use customers with a wide selection of cannabis products, including Harborside’s own KEY branded line of cannabis flower. In addition to the brick and mortar store, DHS functions as one of only two state licensed drive-through dispensaries in all of California, providing consumers with a fast, convenient way to purchase cannabis products.
Upon the closing of the Acquisition, Harborside paid the aggregate Purchase Price comprised of: (a) approximately US$1.5 million in 15,793.40 multiple voting shares based on the 30 day volume-weighted average price of the subordinate voting shares of the Company on the Canadian Securities Exchange at the time of closing of the Acquisition, and US$784,646 in cash consideration for the transfer of the equity interest of Accucanna LLC to the Company; and (b) US$2.6 million in cash for the Property. Harborside expects to finance all or a portion of the Purchase Price owed for the Property after closing of the Acquisition.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian and United States securities legislation. To the extent any forward-looking information in this news release constitutes “financial outlooks” or “future-oriented financial information” within the meaning of applicable Canadian securities laws, the reader is cautioned not to place undue reliance on such information. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the benefits created by the Acquisition, including with respect to expectations of future profitability following the completion of the Acquisition, and statements with respect to the Company’s future licensed cannabis activities at the DHS and plans to finance the Property.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political, social and environmental uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations; the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the quarter ended March 31, 2021 and the Company’s listing statement dated May 30, 2019, which are available under the Company’s profile on www.sedar.com. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company, through several of its subsidiaries, is indirectly involved in the manufacture, possession, use, sale, and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States. Local state laws where the Company operates permit such activities however, investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.
While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with recreational and medicinal cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
(This information is primarily sourced from Harborside Inc.. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
German Cannabis Policy Reform Takes Center Stage at ICBC Berlin 2023
BERLIN-- The International Cannabis Business Conference (ICBC) is gearing up for a timely and significant political discussion on cannabis policy reform in Germany. Building on the historic panel discussion held in 2021, where all major ...
Cronos Group Inc. to Cease Hemp-Based CBD Operations in the U.S. and Focus on Cash Flow and Future THC Market Entry
TORONTO-- Canadian cannabis company Cronos Group Inc. has revealed plans to discontinue its hemp-derived CBD operations in the United States by the end of the second quarter of this year. The decision is aimed at ...
Multi-State-Operators Set to Enter NY Adult-Use Market After Policy Change
NEW YORK–In an effort to stabilize New York's adult-use marijuana program, which has experienced a rocky rollout, new legislation and significant policy shifts have been proposed. One of the key changes is the potential entry ...